Administrative Core
Administrative Core
批准号:
10931064
负责人:
Marina Y Konopleva
金额:
$17.74万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-09-01 至 2024-08-31
关键词:
AddressAdministratorAdvocateAwardBioinformaticsBiometryCancer CenterCancer Center Support GrantCaringCell TherapyClinicClinicalClinical TrialsCollaborationsCommunicationComplexConsultationsDataDecision MakingDevelopmentDoctor of MedicineElectronic MailEligibility DeterminationEnsureFox Chase Cancer CenterGrantInfrastructureInstitutionInterdisciplinary StudyLaboratoriesLeadershipMinorityMonitorNational Cancer InstituteOrganOutcomePathologyPatientsPoliciesPreparationPrognosisProgress ReportsProtocols documentationPublicationsQuality ControlRegulationReportingReproduction sporesResearchResearch ActivityResearch InfrastructureResearch PersonnelResearch Project GrantsSiteStem cell transplantStrategic PlanningSupervisionTexasTissuesTranslational ResearchUnited States National Institutes of HealthUniversitiesUniversity of Texas M D Anderson Cancer CenterWomanWorkcareerdata managementdata sharingdesignexperienceimprovedinterdisciplinary collaborationlecturesleukemiameetingsnovelprogramsquality assurancerecruitscreeningsuccesssymposiumtransplantation therapyweb site
中文摘要
项目总结(行政核心)
行政核心为MD安德森癌症中心和坦普尔/福克斯提供必要的支持
追逐癌症中心白血病孢子PI和调查人员以最大限度地取得成功。该片由戴维斯博士联合执导。
Hagop Kantarkin和Jean-Pierre Issa,他们是执行委员会的联合主席并提供全面监督
在五个项目中,增加了两个核心,即发展研究(DRP)和职业提升(CEP)
程序,以及孢子的科学方向。核心联席董事依靠广泛的广泛基础
内部和外部咨询委员会在关键决策方面的科学、研究和孢子经验-
制作。孢子研究中复杂的跨学科研究的成功取决于不同学科的整合
白血病的研究方法。核心将克服跨学科协作和数据方面的障碍
共享并将确保统一的翻译研究工作。孢子是建立在规划、整合、
以及由该核心支持的翻译研究工作。其领导层和工作人员将负责
监测/规划科学活动;提供科学指导;确保强调翻译
研究;确保与国内外主要白血病计划的跨学科和跨孢子整合
MD安德森和其他广泛的翻译研究活动;并提供最佳的行政和财政
管理层。行政核心的具体职责是:监督和监测所有孢子
活动;促进与孢子相关的临床项目之间的整合和沟通;监督
所有研究项目的科学完整性,并授予奖项;确保遵守机构,
政府和国家癌症研究所的条例;监督财政和预算活动
与内部咨询委员会协调数据控制质量保证问题和
生物统计、数据管理和生物信息学核心(核心3);协调与以下方面相关的活动
临床试验,包括方案的设计、监管机构的批准、实施和资格
对患者进行筛查并将其分配到不同的研究中;为Core 3和
病理学和组织核心(核心2);协调和管理孢子执行委员会的会议,
内部和外部咨询委员会、每月调查员会议、季度研究会议、
讲课和座谈会;管理DRP和CEP;协调跨学科和跨孢子
与其他白血病孢子项目和调查人员的互动和交流/会议,以及
器官现场孢子计划;管理患者权益倡导者的活动;遵守并改进
处理招募和留住妇女和少数族裔的政策;组织研讨会带给MD
安德森顾问和演讲者,在白血病的各种临床和实验室方面具有专业知识
研究;维护白血病孢子网站,专注于白血病翻译研究中的问题。
英文摘要
PROJECT SUMMARY (ADMINISTRATIVE CORE)
The Administrative Core provides essential support to the MD Anderson Cancer Center and Temple/Fox
Chase Cancer Center Leukemia SPORE PIs and investigators to maximize success. It is co-directed by Drs.
Hagop Kantarjian and Jean-Pierre Issa, who co-chair the Executive Committee and provide overall supervision
of five Projects, two additional Cores, Developmental Research (DRP) and Career Enhancement (CEP)
Programs, and scientific direction of the SPORE. The Core co-Directors rely on the extensive broad-based
scientific, research, and SPORE experience of the Internal and External Advisory Boards in critical decision-
making. Success of the complex interdisciplinary research in the SPORE depends on integration of diverse
leukemia research approaches. The Core will overcome barriers to interdisciplinary collaboration and data
sharing and will ensure a unified translational research effort. The SPORE is founded on planning, integration,
and translational research efforts supported by this Core. Its leadership and staff will be responsible for
monitoring/planning scientific activities; providing scientific direction; ensuring emphasis on translational
research; ensuring interdisciplinary and inter-SPORE integration with major leukemia programs within/outside
MD Anderson and other broad translational research activities; and providing optimal administrative and fiscal
management. Specific responsibilities of the Administrative Core are: Oversee and monitor all SPORE
activities; promote integration and communication among the SPORE-related clinical programs; monitor the
scientific integrity of all research projects, and grant awards; assure compliance with institutional,
governmental, and National Cancer Institute regulations; oversee the fiscal and budgetary activities of the
SPORE; coordinate data control quality assurance issues in conjunction with the Internal Advisory Board and
the Biostatistics, Data Management, and Bioinformatics Core (Core 3); coordinate activities associated with
clinical trials, including design of protocols, approval by regulatory bodies, implementation, and eligibility
screening and assignment of patients to different studies; provide oversight and support for Core 3 and the
Pathology and Tissue Core (Core 2); coordinate and manage meetings of the SPORE Executive Committee,
the Internal and External Advisory Boards, monthly investigator meetings, quarterly research meetings,
lectures, and symposia; administer the DRP and the CEP; coordinate interdisciplinary and inter-SPORE
interactions and exchanges/meetings with other Leukemia SPORE programs and investigators, and other
organ-site SPORE programs; administer the activities of the Patient Advocates; comply with, and improve
policies addressing recruitment and retention of women and minorities; organize seminars to bring to MD
Anderson consultants and speakers with expertise in various clinical and laboratory aspects of leukemia
research; maintain a Leukemia SPORE website focused on issues in leukemia translational research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the novel cancer testis antigen HSPA1L as immunotherapeutic target in AML
-
批准号:10625516
-
项目类别:
-
资助金额:$18.56万
-
财政年份:2022
-
负责人:Marina Y Konopleva
-
依托单位:
Defining the novel cancer testis antigen HSPA1L as immunotherapeutic target in AML
-
批准号:10433726
-
项目类别:
-
资助金额:$22.72万
-
财政年份:2022
-
负责人:Marina Y Konopleva
-
依托单位:
Inhibition of Bcl-xL by Targeted Degradation
-
批准号:10737840
-
项目类别:
-
资助金额:$7.28万
-
财政年份:2020
-
负责人:Marina Y Konopleva
-
依托单位:
Chaperone-Mediated Protein Degradation of Bcl-xL and Bcl-2
-
批准号:10599452
-
项目类别:
-
资助金额:$4.7万
-
财政年份:2020
-
负责人:Marina Y Konopleva
-
依托单位:
Inhibition of Bcl-xL by Targeted Degradation
-
批准号:10378075
-
项目类别:
-
资助金额:$49.56万
-
财政年份:2020
-
负责人:Marina Y Konopleva
-
依托单位:
Inhibition of Bcl-xL by Targeted Degradation
-
批准号:10133018
-
项目类别:
-
资助金额:$50.57万
-
财政年份:2020
-
负责人:Marina Y Konopleva
-
依托单位:
Inhibition of Bcl-xL by Targeted Degradation
-
批准号:10644990
-
项目类别:
-
资助金额:$49.56万
-
财政年份:2020
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen
-
批准号:10415997
-
项目类别:
-
资助金额:$9.6万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen
-
批准号:10654631
-
项目类别:
-
资助金额:$4.55万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting mitochondrial complex I in acute lymphoblastic leukemia
-
批准号:9815737
-
项目类别:
-
资助金额:$58.75万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen
-
批准号:10174866
-
项目类别:
-
资助金额:$37.48万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting mitochondrial complex I in acute lymphoblastic leukemia
-
批准号:10437742
-
项目类别:
-
资助金额:$7.0万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen
-
批准号:10745877
-
项目类别:
-
资助金额:$27.09万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting mitochondrial complex I in acute lymphoblastic leukemia
-
批准号:10170323
-
项目类别:
-
资助金额:$61.87万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting mitochondrial complex I in acute lymphoblastic leukemia
-
批准号:10654665
-
项目类别:
-
资助金额:$46.91万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting mitochondrial complex I in acute lymphoblastic leukemia
-
批准号:10745872
-
项目类别:
-
资助金额:$28.74万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Therapeutic targeting of glutamine metabolism in MDS
-
批准号:9117917
-
项目类别:
-
资助金额:$50.69万
-
财政年份:2016
-
负责人:Marina Y Konopleva
-
依托单位:
Therapeutic targeting of glutamine metabolism in MDS
-
批准号:9901359
-
项目类别:
-
资助金额:$48.15万
-
财政年份:2016
-
负责人:Marina Y Konopleva
-
依托单位:
Therapeutic targeting of glutamine metabolism in MDS
-
批准号:9250735
-
项目类别:
-
资助金额:$47.48万
-
财政年份:2016
-
负责人:Marina Y Konopleva
-
依托单位:
Hypoxia-Selective Kinase Inhibitors for Leukemia Therapy
-
批准号:8527296
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2013
-
负责人:Marina Y Konopleva
-
依托单位:
海外基金